drugset / Trial / NCT06243159
JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of refractory autoimmune diseases
Timeline
- Start
- 2024-02-08
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JY231 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |